Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.

In this episode, we dive into:
•⁠ ⁠POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
•⁠ ⁠inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
•⁠ ⁠Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
•⁠ ⁠ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.

Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast

ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka